Long-acting naltrexone has long-acting benefits and 100% induction rates are not difficult to achieve

Affiliations

Comment

Colin Brewer et al. Addiction. 2019 Jan.

. 2019 Jan;114(1):188-189.

doi: 10.1111/add.14448. Epub 2018 Oct 30.

No abstract available

Keywords: Induction rates; long-acting naltrexone; naltrexone; naltrexone-induction; opiate antagonist; opiates.

Comment in

Extended-release injectable naltrexone (XR-NTX): a response to clinical issues raised by Brewer & Streel.
Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow G, Silverman K. Jarvis BP, et al. Addiction. 2019 Jan;114(1):189-190. doi: 10.1111/add.14462. Epub 2018 Oct 30. Addiction. 2019. PMID: 30345640 No abstract available.

Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, Silverman K. Jarvis BP, et al. Addiction. 2018 Jul;113(7):1188-1209. doi: 10.1111/add.14180. Epub 2018 Mar 24. Addiction. 2018. PMID: 29396985 Free PMC article.